Kornimate/medical-research-clean huggingface dataset:
vedolizumab for the treatment of collagenous gastritis

Conditions: Collagenous Gastritis

Summary: the goal of this clinical trial is to learn about how vedolizumab may affect patients with collagenous gastritis (cg). the main questions it aims to answer are: * whether vedolizumab can reduce cg symptoms * whether vedolizumab is safe to take for patients with cg participants in this study will: * receive vedolizumab through an iv ("infusion") * complete a survey at each infusion visit * have blood collected at each infusion visit * undergo an endoscopy with biopsy at 2 timepoints

eligible participants will receive vedolizumab through an iv ("infusion") at week 0, then week 2, then week 6. participants who respond well to the treatment after the first 3 infusions and are interested in continuing will receive vedolizumab every 8 weeks for about 1 year. at each visit, participants will be asked about their collagenous gastritis symptoms and any changes in their health or medications. blood samples will be collected from participants at every vedolizumab infusion. some of these samples will be collected for safety purposes, some will be collected to monitor cg progression, and some will be collected for research purposes. during the screening period and a few months after beginning treatment, the study doctor will perform an upper endoscopy to help determine whether vedolizumab has improved each participant's cg. an upper endoscopy is a procedure where the doctor inserts a small tube with a camera through the mouth and down the throat to look at the upper gastrointestinal tract (the esophagus, stomach, and part of the small intestine). during the procedure, biopsies will be collected to monitor cg and for research purposes. all participants will be given medication to make them comfortable throughout the duration of the procedure, which lasts approximately 10 to 30 minutes.

Eligibility criteria:
inclusion criteria: * age 14 or older * weight of at least 40kg * has a biopsy-confirmed diagnosis of collagenous gastritis * agrees to all required study procedures * presence of one or more collagenous gastritis symptom at a severity of grade 1 or higher at the time of enrollment: abdominal pain, nausea, diarrhea, bloating, vomiting, flatulence, constipation, fatigue, headache, rash exclusion criteria: * unable to independently provide informed consent or assent * allergic to vedolizumab or any of its components

Keywords: collagenous gastritis, vedolizumab
epidemiology of treatment resistant depression in taiwan

Conditions: Depressive Disorder, Treatment-Resistant

Summary: the purpose of this study is to assess the epidemiology of treatment resistant depression (trd) in the nationally insured population in taiwan including incidence, duration of clinical episodes, and prevalence by age and sex.

this is a retrospective study of approximately one million subjects randomly selected from an anonymized database national health insurance research database (nhird). participants aged 18 years or older who have had neither a depression diagnosis nor a dispensing of an antidepressant medication in the last four months of 2004 will enter the study when they receive in 2005 a depression diagnosis and a dispensing of an antidepressant medication within 30 days of each other and will be followed up to 8 years or until they have 4 months with neither a depression diagnosis nor a dispensing of an antidepressant medication. treatment resistant depression (trd) incidence, trd prevalence by age and sex and duration of clinical episodes will be estimated.

Eligibility criteria:
inclusion criteria: * participants who have been continuously enrolled in the insurance plan since january 1, 2004 (ignoring breaks of less than 30 days) and have not received an exclusion diagnosis and during the last 4 months of 2004, a) have not received a diagnosis of depression and b) have not received a dispensing of an ad medication * participants with a diagnosis of a depressive disorder including dysthymic disorder (international classification of diseases \[icd\]-9 codes 296 depression-related, 300.4, 311) and major depressive disorder (icd-9 296.2, 296.3) will be followed through december 31, 2013 exclusion criteria: - participants who receive following diagnosis will be excluded, a) mania, b) schizophrenia (icd-9 codes 295), c) bipolar disorder (icd-9 codes 296 bipolar-related), d) dementia (icd-9 codes 290 or 294); note: major depressive disorder (mdd) with psychotic behavior (icd 296.24 for single episode, icd 296.34 for recurrent episode) is not an exclusion

Keywords: treatment resistant depression
chewing function in pediatric neuromuscular disorders

Conditions: Mastication Disorder

Summary: we aimed to evaluate chewing function (cf) in children with neuromuscular disorders, and investigate reliability of the karaduman chewing performance scale (kcps).

chewing disorders (cd) can be seen due to muscle weakness in children with neuromuscular disorders neuromuscular disorders (nmd). normal diet consists of all food consistencies including liquid, pudding and solid foods, and cd causes inability to intake solid food. this condition can affect development, nutritional behavior and child-parent interaction in children. thus, it is important to determine cd in an early period with appropriate assessment methods and plan appropriate therapies in nmd. we aimed to evaluate chewing function (cf) in children with nmd, and investigate reliability of the karaduman chewing performance scale (kcps).

Eligibility criteria:
inclusion criteria: * children above the age of 2 years * children with neuromuscular disorders exclusion criteria: * children under the age of 2 years * children without neuromuscular disorders

Keywords: mastication children with neuromuscular disorders
busulfan, cyclophosphamide, and autologous stem cell transplant in treating patients with multiple myeloma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Summary: rationale: giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. an autologous stem cell transplant may be able to replace the blood-forming cells that were destroyed by the chemotherapy. purpose: this phase ii trial is studying how well giving busulfan together with cyclophosphamide followed by an autologous stem cell transplant works in treating patients with multiple myeloma.

objectives: primary * to compare relapse-free survival and overall survival of patients with multiple myeloma treated with iv busulfan vs historical control patients treated with oral busulfan when administered with cyclophosphamide as a conditioning regimen prior to autologous hematopoietic stem cell transplantation. secondary * to compare pulmonary toxicity rates of iv busulfan vs oral busulfan when administered with cyclophosphamide as a conditioning regimen prior to autologous hematopoietic stem cell transplantation. outline: patients receive high-dose busulfan iv every 6 hours on days -8 to -4 and high-dose cyclophosphamide iv over 4 hours on days -3 and -2. patients undergo autologous hematopoietic stem cell transplantation on day 0. after completion of study treatment, patients are followed up periodically.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of plasma cell myeloma * patients with cardiac ejection fraction \>= 45% or clearance by cleveland clinic faculty (ccf) cardiologist * patients with diffusion capacity of carbon monoxide (dlco) \>= 45% predicted or clearance by ccf pulmonologist * patient with previously harvested peripheral blood progenitor cells with a minimum of 2 x 10\^6 cd 34+ cells/kg harvested exclusion criteria: * patients receiving total body irradiation * non-myeloablative/reduced-intensity conditioning * pregnant and breast feeding patients * human immunodeficiency virus (hiv) positive * patients with serum creatinine \> 2.0 * prior hematopoietic stem cell (hsc) transplant

Keywords: stage i multiple myeloma stage ii multiple myeloma stage iii multiple myeloma
12 months clinical follow-up of non-carious cervical lesions restored with new injectable composite

Conditions: Dental Erosion

Summary: non-carious cervical lesions are defined as loss of pathological material not associated with caries in the enamel-cement junction of the tooth. the etiology of these lesions has been defined as brush abrasion, acid-induced erosion and abstraction due to microstructure losses due to stress concentration in a particular region of the tooth. these lesions should be restored using minimally invasive techniques. the necessity of restorative treatment is directly related to the size of the lesion, sensitivity and aesthetic requirements. however, restorative procedures are often challenging because the cavity preparation does not provide adequate retention, and often the cervical end margin is positioned under the gingiva. this leads to contamination of the operation site with blood, saliva and gingival fluid. several restorative options have been proposed for the treatment of cervical caries-free lesions. however, due to their high aesthetic properties, improved adhesive capacity and mechanical properties, composites have been accepted as the most suitable choice. clinical studies have demonstrated that marginal adaptation, marginal discoloration, and roughening methods for retention are the most important factors in the clinical performances of composite restorations in cervical lesions. therefore, injectable composites with wettability and better adaptability to cavity margins have been introduced. however, the low filler contents of fluid composites and their weak mechanical properties compared to conventional composites have led researchers to doubt their use in caries-free cervical lesions. as a result of the developed material technology, injectable composites with high filler which have reduced polymerization shrinkage have been developed with simplified filler procedure. however, investigators have not encountered any studies investigating which etching technique this material will exhibit better clinical performance and comparing it with traditional pasty composites. the aim of this study is to evaluate the clinical performance of traditional paste type and injectable composites which will be made by using two different etching techniques.


Eligibility criteria:
inclusion criteria: * patients with cervical lesions in the mouth with multiples of 4 and 4, * patients over 18 years of age and in permanent dentition, * patients who do not have a pulpal or endodontic lesion on their teeth to be treated, * patients without sensitivity to percussion in the teeth to be treated. exclusion criteria: patients with any systemic disease, * pregnant or suspected pregnancy and also breastfeeding patients, * patients who are allergic to any dental material, * patients with any periodontal disease, * patients with poor oral hygiene, * in cases where the teeth are exposed to excessive load due to excessive rupture, * cervical caries lesions, * patients who continue orthodontic treatment, * desensitizing agents or fluoride treatment.
study on pharmacokinetics

Conditions: HIV Infections

Summary: the purpose of this study is to assess the effect of the coadministration of multiple doses of bms-663068 on the systemic exposure of rosuvastatin.


Eligibility criteria:
inclusion criteria: 1. signed informed consent form * signed written informed consent must be obtained from the subjects in accordance with requirements of the study center's irb or iec before the initiation of any protocol-required procedures. 2. target population * healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination findings, vital sign measurements, 12-lead ecg measurements, and clinical laboratory test results. 3. age and reproductive status * men and women of non-childbearing potential, ages 18 to 50 years, inclusive. women must have documented proof that they are not of childbearing potential. women must not be breastfeeding. * males who are sexually active with women of childbearing potential (wocbp) must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s). exclusion criteria: * women who are of childbearing potential or breastfeeding * any significant acute or chronic medical illness * history of rhabdomyolysis or biliary disorders, including gilbert's disease or dubin-johnson disease * smokers (those who currently smoke, as well as those who have stopped smoking less than 6 months prior to the start of study drug administration) * alcohol intake exceeding 2 standard drinks per days; however, no alcohol is allowed 1 week prior to the start of study drug administration and for the duration of the study * any other sound medical, psychiatric, and/or social reason as determined by the investigator
gut microbiota in patients with moyamoya disease

Conditions: Moyamoya Disease; Gut Microbiota

Summary: this study is to find out the association between gut microbiota and moyamoya disease.

moyamoya disease (mmd) is a rare cerebrovascular disorder, it is a major cause of stroke in children and young adults in japan, korea, and china, but its pathogenesis is not yet clear. dysbiosis of gut microbiota may play a role in the pathological change of mmd. in this research, the investigators would perform metagenomic sequencing to find the characteristics of gut microbiota of mmd and to explore the correlations with metabolic, immune, and clinical symptoms. this research will not only help the understanding of the pathophysiology of mmd, but also may provide a reference for the selection of clinical treatment options.

Eligibility criteria:
inclusion criteria: 1. diagnosis of mmd by dsa according to the japanese guidelines published in 2012, 2. stenosis or occlusion of the terminal internal carotid and the proximal middle and anterior cerebral arteries and unilateral or bilateral involvement 3. age: 2-60 years old. exclusion criteria: 1. moyamoya syndrome, 2. pregnancy, 3. evidence of gastrointestinal infection/ inflammation/ obstruction 4. history of partial or total resection of small or large bowel, as well as gut reanastomosis, 5. use of antibiotics within 2 weeks prior to symptoms onset, 6. gastrointestinal malignancy 7. any hospitalization within 3 months before recruitment

Keywords: moyamoya disease microbiome rnf213 p.r4810k mri
ultrasound guided peribulbar anaesthesia - a novel dual quadrant injection technique

Conditions: Eye Diseases

Summary: peribulbar anaesthesia for ocular surgery depends on the spread of local anaesthetic throught the orbit to be successful and has a relatively high failure rate. this study will examine a novel ultrasound guided approach to peribulbar anaesthesia which should extend the depostion of local anaesthetic by using a dual quadrant injection technique. the study will assess the feasibility of this technique, how successful it is and whether any obvious safety issues arise with its use.

peribulbar anesthesia is widely used for anterior and posterior chamber ophthalmic procedures. it is a blind technique which is traditionally carried out by inserting a needle in the infero-lateral aspect of the orbit below the globe and injecting a volume of 8 - 12 ml of local anesthetic in the periorbital space. the goal of this inejction is to achieve akinesia and anesthesia of the eye sufficient for surgery. the technique has a relatively high failure rate of up to 30%. a failure or insufficient block requires a second or rarely a third peribulbar injection to achieve success. ultrasound can be used to guide needles in the human body and has been successfully used in many anatomic locations for anaesthesia. this study will assess whether ultrasound can guide the block needle in ophthalmic anesthesia to deliver local anesthetic via a single entry into two discrete locations within the periorbital space - the first in the infero-lateral quadrant and the second in the infero-medial quadrant. if this can be done the investigators may achieve a higher success rate for this block with a lower volume potentially improving the quality of the block and its safety.

Eligibility criteria:
inclusion criteria: * asa score less than iii and ability to provide a written informed consent * 22 patients presenting for opthalmic surgery exclusion criteria: * coagulation disorder or anticoagulated with inr \> 1.5 * platelet count \< 75 x 10\*9/l * significant myopia (axial length \> 28mm) * patients unable to lie supine for 2 hours * patients with recent gas or silicone injections in/around the eye

Keywords: ultrasound guided peribulbar anesthesia
effect of glucagon-like peptide 1 (glp-1) on microvascular myocardial function in patients with type 2 diabetes.

Conditions: Type 2 Diabetes; Microvascular Dysfunction

Summary: the purpose of the study is to determine if a glp-1 agonist improves microvascular perfusion in the heart of patients with type 2 diabetes


Eligibility criteria:
inclusion criteria: * type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy of metformin and sulfonylurea. * age: 25-75 years * bmi\>25 kg/m2 * hba1c 6,0-10 % exclusion criteria: * current treatment with insulin or dipeptidyl peptidase iv inhibitor. * haemoglobin \< 6.5 mmol/l * documented significant stenosis of the left anterior descending artery (lad) at coronary angiography or ct-angiography or regional dysfunction documented during dipyridamol stress-echocardiography. if stress test at baseline shows significant stenosis the patient will be excluded from the study. * allergy towards victoza ® (liraglutide ), dipyridamol, nitroglycerin or rescue medicine: theophyllin * pregnancy * severe asthma * active cancer * severe co-morbidity with limited life-expectancy * estimated glomerular filtration rate (egfr) \<60 (measured at baseline) * severe hepatic co-morbidity * chronic alcohol abuse * heart failure with a left ventricular ejection fraction \</= 45% * atrial fibrillation * chronic or previous acute pancreatitis * inflammatory bowel disease.

Keywords: diabetes, glp-1, victoza, cfr, microvascular dysfunction
robotic total hip arthroplasty anesthesia management

Conditions: Hip Osteoarthritis; Joint Diseases; Anesthesia

Summary: robotic arthroplasty is increasing in acceptance on a global scale as a result of advancements in orthopedic surgery technology. the investigators aimed to share their anesthesia management experience as well as compare robotic unilateral total hip arthroplasty with conventional surgical technique in this retrospective study.

this study was conducted after obtaining ethics committee approval. the inclusion criteria were as follows: american society of anesthesiologists (asa) physical status i-iii patients between 40-85 years, elective unilateral thas which were performed by a single senior orthopedic surgeon and orthopedic team between january 2021 and january 2023 under csea. exclusion criteria were urgent surgery, bilateral surgery, previous surgery, missing data, and lost to follow-up in the perioperative period. the routine anesthetic protocol for the tka was as follows: a single dose of 0.5% hyperbaric bupivacaine between 15-10 mg was administered intratechally. following this the epidural catheter was inserted 4 cm into the epidural space through the epidural needle and secured. the level of the sensory block was assessed using pin-prick and cold sensation tests, and motor block using the bromage scale. the patients were followed in the postanesthesia care unit (pacu) after the surgery. patients with a modified aldrete scoring system ≥9 were considered to be eligible for the transfer from pacu to the service. pain was evaluated using a visual analogue scale (vas) with regular intervals. data were collected from hospital's electronic database records, patient files, and anesthesia charts.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i-iii * between 40-85 years * elective unilateral thas which were performed by a single senior orthopedic surgeon * between january 2021 and january 2023 under csea. exclusion criteria: * urgent surgery * bilateral surgery * previous surgery * missing data and lost to follow-up in the perioperative period
pet/ct guided fulvestrant therapy for patients with recurrent or metastatic breast cancer

Conditions: Breast Cancer

Summary: purpose: to determine whether \[18f\]fes can predict clinical benefit (defined as complete response, partial response and stable disease ≥ 6 months) to fulvestrant (250 mg im q 28 days) in post-menopausal women with recurrent or metastatic er+ breast cancer who are candidates for further hormonal therapy.

the majority of women diagnosed with breast cancer are post-menopausal, of which up to 75% are estrogen (er) and/or progesterone receptor (pr) positive. even in pre-menopausal breast cancer over half of all patients will have expression of these hormone receptors. thus therapeutic strategies targeting the estrogen receptor or its ligand are the most common treatment offered in breast cancer. despite substantial benefits now demonstrated with selective estrogen receptor modulators (e.g. tamoxifen) and aromatase inhibitors (e.g. anastrazole, letrozole and exemestane), a significant proportion of patients will still unfortunately have or develop resistance to these hormonal therapies. despite approximately two-thirds of patients who are prescribed fulvestrant following prior hormonal agents not benefiting from this therapy, clinicians are still offering this option to all suitable women because of the lack of a better means of identifying the individual responders. to assess whether the recommended treatment is beneficial to a specific individual, the disease burden is assessed before and following treatment. conventional imaging techniques such as the bone scan or computerized tomography (ct) can take several months to show a successful response to treatment. positron emission tomography (pet) can improve the evaluation of women with breast cancer by providing an accurate assessment of the extent of disease and unique information about tumor biology such as metabolic activity.

Eligibility criteria:
inclusion criteria: * post-menopausal (≥ 60 years old, or age ≥ 45 years with amenorrhea for \> 12 months or follicle stimulating hormone and estrogen levels within post-menopausal range, or prior bilateral oophorectomy) * hormone receptor positive (er and/or pgr) disease as determined locally * who performance status 0-2 * life expectancy of ≥ 3 months * the presence of at least one measurable or evaluable (non-measurable) lesion * informed consent prior to any study procedures exclusion criteria: * life threatening metastatic visceral disease * brain or leptomeningeal metastases * prior exposure to fulvestrant * history of bleeding diathesis or need for long term anti-coagulation

Keywords: post-menopausal hormone receptor positive recurrent/metastatic breast cancer. pet/ct recurrent or metastatic